OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic partnerships. However, stiff competition and overdependence on RAYALDEE pose concerns.
Shares of this Zacks Rank #3 (Hold) company have gained 18.3% so far this year against the industry's 3.1% decline. The S&P 500 has decreased 3.3% in the said time frame.
This renowned multinational biopharmaceutical and diagnostics company has a market capitalization of $1.19 billion. The company predicts 30% growth for fiscal 2026 and expects to maintain its strong performance. OPKO Health’s earnings surpassed estimates in three of the trailing four quarter and missed once, the average beat being 73.66%.
Zacks Investment Research
Image Source: Zacks Investment Research
Factors Favoring OPK Stock
Potential of RAYALDEE: Within the pharmaceutical business, Rayaldee has been OPKO Health’s leading renal product in the U.S. market for the last two years. It is the first and only therapy approved by the FDA for the treatment of SHPT in adults with stage three or four chronic kidney disease and vitamin D insufficiency. Rayaldee has been experiencing decent momentum, thanks to the sales team's successful efforts.
The drug is distributed in the United States primarily through the retail pharmacy channel, which is initiated by the largest wholesalers in the United States (collectively known as Rayaldee Customers). In the fourth quarter, Rayaldee saw steady demand, supported by ongoing market adoption and strategic initiatives.
Growth should be driven by expanded indications, geographic expansion and improved reimbursement in 2025. Strong clinical data and potential partnerships position Rayaldee for increased market penetration and broader patient access this year.
Pipeline Progess Buoys Optimism: OPKO Health’s pipeline is advancing across multiple areas. Somatrogon (NGENLA), approved for the treatment of pediatric growth hormone deficiency, is undergoing post-approval expansion. Rayaldee is in further clinical development for non-dialysis CKD patients. Pegzilarginase, in late-stage trials, shows strong efficacy for rare metabolic disorders.
OPKO is also investing in gene therapy and molecular diagnostics, with early to mid-stage programs in development. With a focus on endocrinology, nephrology and rare diseases, the company is well-positioned for growth. Clinical advancements, regulatory milestones and strategic collaborations should drive OPKO’s long-term success in delivering innovative therapies to the market.
OPKO Health’s ModeX Therapeutics continues advancing its innovative pipeline in infectious diseases and oncology. MDX-2201, a next-generation Epstein-Barr virus (EBV) vaccine, is in early clinical development with the NIH, targeting EBV-related diseases like multiple sclerosis and cancers. ModeX is also progressing multispecific antibody therapies for cancer and viral infections, currently in preclinical to early clinical stages, leveraging its proprietary platform to address high unmet needs. As a strategic asset for OPKO, ModeX’s cutting-edge therapies in immuno-oncology and infectious diseases could drive future growth, with clinical advancements and potential partnerships serving as key catalysts.
Strong Q4 Results: OPKO Health exited the fourth quarter of 2024 with better-than-expected results and encouraging top and bottom-line results. Robust revenues from the transfer of intellectual property and other were registered during the quarter. The expansion of the gross margin bodes well for the company.
Management confirmed that enrollment and dosing are underway in the Phase 1 EBV vaccine trial, conducted by OPK's partner, Merck. Additionally, enrollment is underway in the Phase 1 trial of MDX2001 for the treatment of solid tumor cancers. These raise our optimism for the stock. The company has also been awarded $51 million of additional funding under an existing BARDA contract to develop COVID-19 multispecific antibodies and initiate an influenza program. This is also encouraging. During the quarter, BioReference Health made significant strides toward near-term profitability, which looks promising.
Factors That May Offset the Gains for OPK
Overdependence on RAYALDEE: OPKO Health's financial success depends heavily on the commercialization of Rayaldee, its only approved pharmaceutical product in the United States. Failure to effectively market Rayaldee could severely affect the company's revenues, profitability and overall business operations.
Additionally, Rayaldee's market reputation, safety and perceived efficacy are crucial. Any negative publicity, safety concerns or rumors about the product could significantly harm OPKO's business, undermining the product's acceptance and damaging its financial outlook.
Currently, reimbursement challenges, increased competition and slower-than-expected market adoption are likely to hurt Rayaldee sales going forward. Moreover, pricing pressures and formulary restrictions, along with shifts in treatment guidelines and generic alternatives, are likely to keep the drug’s sales under pressure.
Margins Under Pressure: OPKO Health’s operational costs and profitability concerns stem from high R&D expenses, manufacturing costs and investments in commercialization efforts. The diagnostics segment, including BioReference Laboratories, faces margin pressures due to declining COVID-19 testing revenues, increased competition and reimbursement cuts. Meanwhile, the therapeutics division requires significant investment in clinical trials, regulatory processes, and market expansion for products like Rayaldee and Somatrogon.
Scaling ModeX’s multispecific antibody and vaccine programs adds to the financial strain. Balancing R&D investments, cost efficiencies and revenue growth will be crucial for OPKO in improving profitability and sustaining long-term financial health.
OPKO Health, Inc. Price
OPKO Health, Inc. Price
OPKO Health, Inc. price | OPKO Health, Inc. Quote
Estimate Trend of OPK
OPKO Health is witnessing a positive estimate revision trend for 2025. In the past 30 days, the Zacks Consensus Estimate for its loss has narrowed from 26 cents to 23 cents per share.
The Zacks Consensus Estimate for the company’s first-quarter 2025 revenues and loss per share is pegged at $163.2 million and 7 cents, respectively. The revenue estimate indicates a 6.1% decline from the year-ago quarter’s reported number, while earnings are estimated to improve 41.7%.
Stocks to Consider
Some better-ranked stocks in the broader medical space are Masimo MASI, Cencora, Inc. COR and Boston Scientific Corporation BSX.
Masimo, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 20% for 2025. MASI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.41%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo’s shares have gained 0.7% against the industry’s 3% decline so far this year.
Cencora, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 12.1%. COR’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 4.9%.
Cencora’s shares have gained 19.5% compared to the industry’s 6% decline year to date.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.3%.
Boston Scientific’s shares have rallied 15.4% compared with the industry’s 7.2% growth so far this year.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
